Streetbeat News

Stock Prices

ALK

HA

Hawaiian Holdings shares are trading higher after the company and Alaska Air agreed with the DoJ to further extend the review period until August 20, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:17 pm

SXTP

60 Degrees Pharmaceuticals shares are trading higher following the company's announcement of a year-over-year increase in Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:15 pm

RILY

B. Riley Financial shares have resumed trading after a temporary halt. The resumption of trading could indicate the resolution of an issue or the release of significant information.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:14 pm

BFRI

Biofrontera shares are trading higher following the release of their Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:14 pm

CMG

SBUX

WMT

YUM

Starbucks' stock surged by 20%, adding over $15 billion in valuation, following the announcement of Brian Niccol as the new CEO. Niccol, previously CEO of Chipotle and Taco Bell, has a net worth of over $300 million. He will receive $85 million in cash and stock from Starbucks.

Portfolio Pulse from Aaron Bry

August 15, 2024 | 2:13 pm

ASTS

AST SpaceMobile shares are trading higher following the company's announcement that its first five commercial satellites are on target for an orbital launch in the first half of September.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:13 pm

RILY

B. Riley Financial shares have been halted to the downside, with the stock now down by 22.67%.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:11 pm

SLNH

Soluna shares are trading higher after the company reported a year-over-year increase in Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:11 pm

INCY

SNDX

The FDA has approved Incyte Corporation (NASDAQ: INCY) and Syndax Pharmaceuticals Inc’s (NASDAQ: SNDX) drug Niktimvo for chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy. This approval is based on the AGAVE-201 study, which showed a 75% overall response rate within the first six months of treatment. Niktimvo will be co-commercialized by Incyte and Syndax in the U.S., with Incyte holding exclusive commercialization rights outside the U.S. The companies plan to launch smaller vial sizes by early Q1 2025.

Portfolio Pulse from Vandana Singh

August 15, 2024 | 2:11 pm

NXGL

NexGel shares are trading lower following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:09 pm